Health

Cancer and the Heart; COVID and Dx Delays; Not the Same Old Accelerated Approval?

The European Society of Cardiology has launched a clinical trial to evaluate cardiac MRI during chemotherapy to prevent treatment-related heart failure in patients with cancer.

A large retrospective study showed that patients with heart failure had a significantly increased risk of developing cancer. (ESC Heart Failure)

The American Heart Association awarded $11 million in grants to support research into disparities in cardio-oncology.

Patients with relapsed/refractory large B-cell lymphoma had significantly better event-free survival if they received the CAR T-cell therapy axicabtagene ciloleucel (Yescarta) instead of chemotherapy plus stem cell transplantation, Kite announced.

More evidence that the COVID-19 pandemic led to delays in cancer diagnosis and cancer-related surgery. (Journal of the National Cancer Institute)

Patients with multiple myeloma had highly variable responses to two doses of mRNA COVID-19 vaccination. (Cancer Cell)

“There is no reason why people cannot do randomized studies to get the drugs approved,” said Richard Pazdur, MD, of the FDA’s Oncology Center of Excellence, during an advisory committee meeting, possibly signaling a change of direction for the agency’s accelerated approval process for cancer drugs. (Endpoints News)

A type of laser surgery for early-stage bladder cancer may help reduce surgical complications and the risk of recurrence. (Cedars-Sinai Medical Center)

Exelixis and Ipsen announced that the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) significantly improved progression-free survival as first-line treatment for advanced liver cancer.

A phase III trial of the chemokine receptor antagonist balixafortide plus eribulin for previously treated advanced HER2-negative breast cancer showed no improvement in the co-primary endpoint of objective response rate or the key secondary endpoint of clinical benefit rate versus eribulin alone, Polyphor announced.

Historically, prostate cancer responds poorly to immunotherapy, but a new study suggests a fourth of prostate cancers have molecular characteristics favorable for treatment with immune checkpoint inhibitors. (Clinical Cancer Research)

Assisted reproduction techniques did not increase subsequent risk of cancer in children and young adults. (European Society of Human Reproduction and Embryology)

Puma Biotechnology announced expanded FDA approval of neratinib (Nerlynx) to include both early-stage and metastatic HER2-positive breast cancer.

  • Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.